Treatment of mood and anxiety disorders
The invention relates to a selective inhibitor of Elk-1 or MSK-1 activation for use in the prevention and/or treatment of mood and anxiety disorders.
1. A method for treating or preventing depression in a subject in need thereof, said method comprising administering a therapeutically effective amount of at least one selective peptide inhibitor of E twenty-six (ETS)-like transcription factor 1 (Elk-1) activation or a therapeutically effective amount of a pharmaceutical composition comprising such a selective peptide inhibitor of Elk-1 activation,
wherein said peptide inhibitor is a peptide comprising at least one cell penetrating sequence and at least one docking domain sequence where the docking domain is a peptide consisting of the amino acid sequence
SPAKLSFQFPSSGSAQVHI (SEQ ID NO:1).
2. The method according to claim 1 , further comprising the combined administration of at least one antidepressant drug.
3. The method of claim 1 , wherein said cell penetrating sequence is chosen from the group consisting of HIV-TAT sequence (SEQ ID NO: 4); Penetratin (SEQ ID NO: 5); and amino acid sequences of SEQ ID NO: 6 to 10 and of (SEQ ID NO: 15 to 19.
4. The method of claim 1 , wherein said peptide inhibitor has the sequence of SEQ ID NO: 28.